Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer

Incyte (INCY) Tops Q4 EPS by 20c

February 11, 2016 8:34 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.29, $0.20 better than the analyst estimate of $0.09. Revenue for the quarter came in at $243.9 million versus the consensus estimate of $225.92 million.

2016 guidance for Jakafi net product revenues in the range of $800 million to $815 million, reflecting expectations for... More